MINT-NADOLOL 80 MG — DIN 02496399

What is MINT-NADOLOL?

MINT-NADOLOL 80 MG contains NADOLOL : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02496399, held by MINT PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Aug-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is MINT-NADOLOL used for?

MINT-NADOLOL (nadolol) is indicated for prophylaxis of angina pectoris. MINT-NADOLOL is indicated in patients with mild or moderate hypertension. MINT-NADOLOL is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a beta-blocker rather than a diuretic. The combination of nadolol with a diuretic has been found to be compatible and generally more effective than nadolol alone. In a few cases where peripheral vasodilators were used with nadolol, no evidence of incompatibility was seen. MINT-NADOLOL is not recommended for the emergency treatment of hypertensive crises.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How is it administered?

It is recommended that MINT-NADOLOL (nadolol) be administered as a single daily dose. MINT-NADOLOL may be administered without regard to meals since the presence of food in the gastrointestinal tract does not affect the rate or extent of nadolol absorption. MINT-NADOLOL dosage must always be adjusted to the individual needs of the patient, in accordance with the following guidelines: Angina Pectoris: MINT-NADOLOL treatment should be initiated with doses of 80 mg daily. If an adequate response is not observed after one week, dosage may be increased by 80 mg increments at weekly intervals, until a satisfactory response is achieved. The maximum recommended daily dose is 240 mg. Patients stabilized on 80 mg daily might be tried on 40 mg daily as this dose has been found to be effective in some cases. The value and safety of doses above 240 mg daily in angina pectoris have not been established. Hypertension: MINT-NADOLOL treatment should be initiated with doses of 80 mg daily. If an adequate response is not observed after one week, dosage may be increased by 80 mg increments at weekly intervals, until a satisfactory response is achieved. The maximum recommended daily dose is 320 mg, although most patients respond to 240 mg or less. The value and safety of doses above 320 mg daily have not been established.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

Allergic rhinitis, bronchospasm (including bronchial asthma), or severe chronic obstructive pulmonary disease. Sinus bradycardia. Second and third degree A-V block. Right ventricular failure secondary to pulmonary hypertension. Congestive heart failure. Cardiogenic shock. Anesthesia with agents that produce myocardial depression, e.g. ether. Hypersensitivity to nadolol. Severe liver disease. Serious problems with blood flow in your feet and legs (peripheral artery disease). Galactose intolerance, Lapp lactase deficiency, Glucose-galactose malabsorption. Patients 18 years and younger.

Warnings and precautions

Special cautions should be exercised when administering MINT-NADOLOL (nadolol) to patients with a history of heart failure. Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and inhibition with beta blockade always carries a potential hazard of further depressing myocardial contractility and precipitating cardiac failure. In patients without a history of cardiac failure, continued depression of the myocardium over a period of time can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of impending cardiac failure during MINT-NADOLOL therapy, patients should be fully digitalized, and/or given a diuretic, and the response observed closely. Nadolol acts selectively without blocking the inotropic action of digitalis on the heart muscle. However, the positive inotropic action of digitalis may be reduced by the negative inotropic effect of nadolol when the two drugs are used concomitantly. The effects of nadolol and digitalis are additive in depressing A-V conduction. If cardiac failure continues despite adequate digitalization and diuretic therapy MINT-NADOLOL therapy should be discontinued. Patients with angina should be warned against abrupt discontinuation of MINT-NADOLOL. There have been reports of severe exacerbation of angina, and of myocardial infarction or ventricular arrhythmias occurring in patients with angina pectoris, following abrupt discontinuation of beta- blocker therapy. The last two complications may occur with or without preceding exacerbation of angina pectoris. Therefore, when discontinuation of MINT-NADOLOL is planned in patients with angina pectoris, the dosage should be gradually reduced over a period of about 2 weeks and the patient should be carefully observed. The same frequency of administration should be maintained. In situations of greater urgency, MINT-NADOLOL therapy should be discontinued stepwise and under conditions of closer observation. If angina markedly worsens or acute coronary insufficiency develops, it is recommended that treatment with MINT-NADOLOL be reinstituted promptly, at least temporarily. Various skin rashes and conjunctival xerosis have been reported with beta-blockers including nadolol. A severe syndrome (oculo-muco-cutaneous syndrome) whose signs include conjunctivitis sicca and psoriasiform rashes, otitis and sclerosing serositis has occurred with the chronic use of one beta-adrenergic-blocking agent (practolol). This syndrome has not been observed with nadolol or any other such agent. However, physicians should be alert to the possibility of such reactions and should discontinue treatment in the event that they occur. Severe sinus bradycardia due to unopposed vagal activity occurs in approximately 3% of patients following administration of nadolol. In such cases, dosage should be reduced or the use of intravenous atropine could be considered; if no improvement is seen, intravenous isoproterenol should be considered. In patients with thyrotoxicosis, nadolol may give a false impression of improvement by diminishing peripheral manifestations of hyperthyroidism without improving thyroid function; therefore, abrupt withdrawal may be followed by an exacerbation of the symptoms of hyperthyroidism, including thyroid storm.